NYMC Faculty Publications

Document Type

Article

Publication Date

7-26-2016

Department

Medicine

Abstract

BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.

CASE PRESENTATION: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.

CONCLUSION: This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab.

Publisher's Statement

Originally published in Experimental Hematology & Oncology. Licensed under CC-BY 4.0. https://doi.org/10.1186/s40164-016-0051-4

Included in

Oncology Commons

Share

COinS